BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium, December 10 – 13
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium, December 10 – 13
- Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT plus immune check point inhibitor in metastatic breast cancer
- Presentations include planned Phase 3 study design expanding use of Bria-IMT + CPI to any cancer patient with central nervous system (CNS) metastases
- BriaCell將展示5個海報,重點介紹Bria-IMt與免疫檢查點抑制劑聯合在轉移性乳腺癌中的第2期試驗更新存活和關鍵生物標誌數據
- 報告將包括計劃中的第3期研究設計,將Bria-IMt + CPI的使用擴展到任何患有中樞神經系統(CNS)轉移的癌症患者
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces five posters, including a Spotlight poster presentation, at the San Antonio Breast Cancer Symposium (SABCS) 47th Annual Meeting, being held December 10 – 13 , 2024, at the Henry B. Gonzalez Convention Center, San Antonio, Texas.
PHILADELPHIA和溫哥華,不列顛哥倫比亞,2024年11月04日(全球新聞專線)-生物技術公司BriaCell Therapeutics Corp。(納斯達克:BCTX,BCTXW)(tsx:BCT)("BriaCell"或"公司"),一家開發新型免疫療法以改變癌症治療的臨床生物技術公司,宣佈在2024年12月10日至13日於德州聖安東尼奧亨利B.岡薩雷斯會議中心舉行的第47屆聖安東尼奧乳腺癌研討會(SABCS)年會上發表五篇海報,其中包括一篇重點海報展示。
"At BriaCell, we remain committed to advancing our novel therapies to improve cancer patients' lives," stated William V. Williams, MD, BriaCell's President & CEO. "Having five poster presentations, including a spotlight poster, attests to the depth and breadth of our research and clinical development efforts at BriaCell. We look forward to sharing our data with scientific experts and cancer specialists seeking better clinical outcomes."
"在BriaCell,我們致力於推進我們的新型療法,改善癌症患者的生活,"BriaCell總裁兼首席執行官威廉姆斯博士說。"擁有五個海報展示,包括一個焦點海報,證明了BriaCell在研究和臨床開發方面的深度和廣度。我們期待與尋求更好臨床結果的科學專家和癌症專家分享我們的數據。"
The details about the Spotlight presentation and other poster sessions are as follows:
關於焦點演示和其他海報展示的詳細信息如下:
Abstract Number: SESS-1071 (Spotlight Poster)
Title: Overall survival results of Bria-IMT allogenic whole cell-based cancer vaccine
Time: Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST
Presentation ID: PS3-06
摘要編號:SESS-1071(重點海報)
標題:Bria-IMt異基因全-電芯癌症生物-疫苗的總體存活結果
時間:2024年12月11日週三 上午7:00 – 上午8:30 CST
演示編號:PS3-06
Abstract Number: SESS-1431
Title: Identification of antigenic determinants in SV-BR-1 derived cellular breast cancer vaccines
Time: Wednesday, December 11, 2024 5:30 – 7:00 PM CST
Presentation ID: P2-06-02
摘要編號:SESS-1431
標題:鑑定SV-BR-1衍生細胞乳腺癌疫苗中的抗原決定因子
時間:2024年12月11日週三 下午5:30 – 7:00 北京時間
演講標識:P2-06-02
Abstract Number: SESS-2217
Title: PD-L1 upregulation in circulating tumor associated cells predicts for clinical outcomes in a phase I/II clinical trial using SV-BR-1-GM vaccine with the checkpoint inhibitor retifanlimab in metastatic breast cancer patients, an interim analysis
Time: Wednesday, December 11, 2024 12:00 – 2:00 PM CST
Presentation ID: P1-01-17
摘要編號:SESS-2217
標題:PD-L1上調在循環腫瘤相關細胞中預測第I/II期臨床試驗中使用SV-BR-1-Gm生物-疫苗與檢查點抑制劑retifanlimab治療轉移性乳腺癌患者的臨床結果,中期分析
時間:2024年12月11日星期三 下午12:00 – 2:00 CST
演講標識:P1-01-17
Abstract Number: SESS-1068
Abstract Title: ASTRO-VAC CNS: Bria-IMT in the management of tumor agnostic metastatic CNS lesions
Time: Wednesday, December 11, 2024 5:30 – 7:00 PM CST
Presentation ID: P2-10-24
摘要編號:SESS-1068
摘要標題:ASTRO-VAC CNS:Bria-IMt在處理瘤特異性轉移性中樞神經系統病變中的應用
時間:2024年12月11日週三 下午5:30 – 7:00 北京時間
演示編號:P2-10-24
Abstract Number: SESS-1069
Title: Bria-IMT CD8+ tumor infiltrating lymphocytes turn "Cold" tumor "Hot" in metastatic breast cancer
Time: Friday, December 13, 2024 12:00 PM – 2:00 PM CST
Presentation ID: P5-10-12
摘要編號:SESS-1069
標題:Bria-IMt CD8+腫瘤浸潤淋巴細胞在轉移性乳腺癌中將"Cold"腫瘤轉化爲"Hot"
時間:2024年12月13日週五 下午12:00 – 2:00 北京時間
展示編號: P5-10-12
Following the presentation, copies of the posters will be posted on .
展示結束後,海報副本將被張貼在。
About BriaCell Therapeutics Corp.
關於BriaCell Therapeutics Corp。
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at .
BriaCell是一家臨床階段的生物技術公司,開發新穎的免疫療法,改變癌症治療。更多信息請訪問。
Safe Harbor
免責聲明
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell continuing to advance its novel targeted immunotherapy candidates; and BriaCell sharing data with scientific experts and cancer specialists are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
本新聞稿包含大量面臨重大風險和不確定性的「前瞻性聲明」。除了歷史事實陳述之外,本新聞稿中的所有內容屬於前瞻性聲明。本新聞稿中的前瞻性聲明可以通過使用諸如「預期」,「相信」,「考慮」,「可能」,「估計」,「期望」,「打算」,「尋求」,「可能」,「也許」,「計劃」,「潛在」,「預測」,「項目」,「目標」,「目標」,「應該」,「將」,「願意」或這些詞的否定形式或其他類似表達來確定,儘管並非所有前瞻性聲明都包含這些詞。關於BriaCell繼續推進其新型靶向免疫療法候選者;以及BriaCell與科學專家和癌症專家分享數據的前瞻性聲明,均基於BriaCell目前的預期且受困難預測的固有不確定性,風險和假設的影響。此外,某些前瞻性聲明,如那些基於未來事件假設的聲明,可能未能證明準確。這些和其他風險和不確定因素在公司最近的《管理層討論和分析》中更全面地描述,在公司最近的《年度信息形式》的「風險因素」一節下描述,在公司的其他文件中的「風險和不確定因素」一節下描述,這些信息均可在公司在SEDAR+的資料中獲得 和 www.sec.gov此公告中包含的前瞻性聲明截至本日期,BriaCell Therapeutics Corp. 除依適用法律要求外,無需更新該信息。
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所及其監管服務提供商(該術語的定義在多倫多證券交易所政策中)對本發佈的充分性或準確性不承擔責任。
Contact Information
聯繫信息
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
公司聯繫人:
William V. Williams,MD
總裁兼首席執行官
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
CORE IR
julesa@coreir.com
媒體關係:
Jules Abraham
CORE IR
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
投資者關係聯繫人:
CORE IR
investors@briacell.com
譯文內容由第三人軟體翻譯。